DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.

Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.

Type
Public
HQ
Cupertino, US
Size (employees)
106 (est)+9%
Website
durect.com
Durect is headquartered in Cupertino, US

Key People at Durect

James E. Brown

James E. Brown

President and Chief Executive Officer
Matthew J. Hogan

Matthew J. Hogan

CFO
Felix Theeuwes

Felix Theeuwes

CSO

Durect Office Locations

Durect has an office in Cupertino
Cupertino, US (HQ)
DURECT 10260 Bubb Rd

Durect Metrics

Durect Financial Metrics

Revenue (2016)

$14 m

Revenue growth (2015-16), %

(27%)

Gross profit

$8.7 m

Gross profit margin (2016), %

62%

Net income (2016)

($34.5 m)

Market capitalization (21-Mar-2017)

$131.9 m

Closing share price (21-Mar-2017)

$0.9

Cash (31-Dec-2016)

$5.4 m
Durect's current market capitalization is $131.9 m.
Durect's revenue was reported to be $14 m in FY, 2016 which is a 26.7% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$15.3 m$19.4 m$19.1 m$14 m

Revenue growth, %

27%(1%)(27%)

Cost of goods sold

$4.8 m$5.7 m$3.9 m$5.3 m

Gross profit

$10.5 m$13.7 m$15.2 m$8.7 m

Gross profit Margin, %

68%71%80%62%

R&D expense

$18.9 m$22.4 m$24.3 m$29.3 m

General and administrative expense

$12.7 m$12.3 m$11.6 m$11.8 m

Operating expense total

$36.5 m$40.4 m$39.8 m$46.4 m

EBIT

($21.2 m)($21 m)($20.7 m)($32.4 m)

EBIT margin, %

(138%)(108%)(108%)(231%)

Interest expense

$284 k$1.2 m$2.2 m$2.3 m

Interest income

$39 k$237 k$143 k

Net Income

($21.5 m)($22.1 m)($22.7 m)($34.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$7.8 m$2.7 m$3.6 m$5.4 m

Accounts Receivable

$2.3 m$2.1 m$2.2 m$1.2 m

Inventories

$3.5 m$3.6 m$3.9 m$3.8 m

Current Assets

$28.3 m$39.5 m$38.3 m$32.4 m

PP&E

$2 m$1.7 m$1.6 m$1.3 m

Goodwill

$6.4 m$6.4 m$6.4 m$6.4 m

Total Assets

$40.8 m$50.1 m$46.8 m$40.5 m

Accounts Payable

$736 k$1 m$1.3 m$2.1 m

Current Liabilities

$7.2 m$7 m$7.4 m$28.8 m

Additional Paid-in Capital

$391.5 m$401.3 m$420.5 m$448.4 m

Retained Earnings

($360.8 m)($382.9 m)($405.6 m)($440.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($21.5 m)($22.1 m)($22.7 m)($34.5 m)

Depreciation and Amortization

$558 k$601 k$425 k$416 k

Accounts Receivable

($183 k)$227 k($100 k)$1.1 m

Inventories

($681 k)($1.4 m)($579 k)($552 k)

Accounts Payable

($1 m)$285 k$265 k$800 k

Cash From Operating Activities

($15.4 m)($14.2 m)($20.6 m)($27.3 m)

Purchases of PP&E

($69 k)($204 k)($225 k)($147 k)

Cash From Investing Activities

$1.1 m($15.7 m)$6.3 m$6 m

Cash From Financing Activities

$11 m$24.8 m$15.2 m$23.1 m

Interest Paid

$6 k$691 k$1.6 m$1.6 m

Durect Market Value History

Durect Company Life

You may also be interested in